APA (7th ed.) Citation

I, R., B, M., A, V., L, Z., P, B., NH, N., & M, M. (2025). An analysis of cost-saving in the German statutory health insurance system due to the introduction of epoetin alfa biosimilars in Germany. Frontiers in public health, 13, 1667315. https://doi.org/10.3389/fpubh.2025.1667315

Chicago Style (17th ed.) Citation

I, Raitner, Müller B, Vijayan A, Zimmermann L, Bramlage P, Ness NH, and Müller M. "An Analysis of Cost-saving in the German Statutory Health Insurance System Due to the Introduction of Epoetin Alfa Biosimilars in Germany." Frontiers in Public Health 13 (2025): 1667315. https://doi.org/10.3389/fpubh.2025.1667315.

MLA (9th ed.) Citation

I, Raitner, et al. "An Analysis of Cost-saving in the German Statutory Health Insurance System Due to the Introduction of Epoetin Alfa Biosimilars in Germany." Frontiers in Public Health, vol. 13, 2025, p. 1667315, https://doi.org/10.3389/fpubh.2025.1667315.